How do i treat inflammatory breast cancer?

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Opinion statement: Inflammatory breast cancer (IBC) is an uncommon and aggressive presentation of locally advanced breast cancer that is potentially curable when localized but may be associated with distant metastasis in up to one-third of patients at presentation. The diagnosis of IBC is made based on clinical features, including the presence of skin edema and erythema involving at least one-third of the breast, with or without a mass, and usually associated with dermal lymphatic invasion (DLI) on skin biopsy. Management requires combined modality therapy, including neoadjuvant chemotherapy with an anthracycline and taxane-based regimen, followed by surgery and radiotherapy, plus concurrent anti-HER2 therapy for HER2-positive disease, and endocrine therapy for at least 5 years after surgery for estrogen-receptor-positive disease (Fig. 1). There have been few large clinical trials focused on IBC; therefore, most data regarding treatment are derived from retrospective analyses, small studies, and extrapolation of results from trials of noninflammatory locally advanced breast cancer. Patients with IBC should be encouraged to enroll in clinical trials whenever possible. In addition, further research into the biology of IBC may help to elucidate the mechanisms underlying its aggressive clinical behavior and to assist in the development of therapies targeted for this specific population.

Original languageEnglish (US)
Pages (from-to)66-74
Number of pages9
JournalCurrent Treatment Options in Oncology
Volume14
Issue number1
DOIs
StatePublished - 2013

Fingerprint

Inflammatory Breast Neoplasms
Skin
Clinical Trials
Breast Neoplasms
Endocrine System Diseases
Combined Modality Therapy
Anthracyclines
Therapeutics
Erythema
Estrogen Receptors
Edema
Breast
Radiotherapy
Neoplasm Metastasis
Biopsy
Drug Therapy
Research
Population

Keywords

  • Anthracycline
  • Inflammatory breast cancer
  • Taxane
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

How do i treat inflammatory breast cancer? / Makower, Della F.; Sparano, Joseph A.

In: Current Treatment Options in Oncology, Vol. 14, No. 1, 2013, p. 66-74.

Research output: Contribution to journalArticle

@article{3e11b5aacaeb4219bacc94052fa14857,
title = "How do i treat inflammatory breast cancer?",
abstract = "Opinion statement: Inflammatory breast cancer (IBC) is an uncommon and aggressive presentation of locally advanced breast cancer that is potentially curable when localized but may be associated with distant metastasis in up to one-third of patients at presentation. The diagnosis of IBC is made based on clinical features, including the presence of skin edema and erythema involving at least one-third of the breast, with or without a mass, and usually associated with dermal lymphatic invasion (DLI) on skin biopsy. Management requires combined modality therapy, including neoadjuvant chemotherapy with an anthracycline and taxane-based regimen, followed by surgery and radiotherapy, plus concurrent anti-HER2 therapy for HER2-positive disease, and endocrine therapy for at least 5 years after surgery for estrogen-receptor-positive disease (Fig. 1). There have been few large clinical trials focused on IBC; therefore, most data regarding treatment are derived from retrospective analyses, small studies, and extrapolation of results from trials of noninflammatory locally advanced breast cancer. Patients with IBC should be encouraged to enroll in clinical trials whenever possible. In addition, further research into the biology of IBC may help to elucidate the mechanisms underlying its aggressive clinical behavior and to assist in the development of therapies targeted for this specific population.",
keywords = "Anthracycline, Inflammatory breast cancer, Taxane, Trastuzumab",
author = "Makower, {Della F.} and Sparano, {Joseph A.}",
year = "2013",
doi = "10.1007/s11864-012-0214-4",
language = "English (US)",
volume = "14",
pages = "66--74",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - How do i treat inflammatory breast cancer?

AU - Makower, Della F.

AU - Sparano, Joseph A.

PY - 2013

Y1 - 2013

N2 - Opinion statement: Inflammatory breast cancer (IBC) is an uncommon and aggressive presentation of locally advanced breast cancer that is potentially curable when localized but may be associated with distant metastasis in up to one-third of patients at presentation. The diagnosis of IBC is made based on clinical features, including the presence of skin edema and erythema involving at least one-third of the breast, with or without a mass, and usually associated with dermal lymphatic invasion (DLI) on skin biopsy. Management requires combined modality therapy, including neoadjuvant chemotherapy with an anthracycline and taxane-based regimen, followed by surgery and radiotherapy, plus concurrent anti-HER2 therapy for HER2-positive disease, and endocrine therapy for at least 5 years after surgery for estrogen-receptor-positive disease (Fig. 1). There have been few large clinical trials focused on IBC; therefore, most data regarding treatment are derived from retrospective analyses, small studies, and extrapolation of results from trials of noninflammatory locally advanced breast cancer. Patients with IBC should be encouraged to enroll in clinical trials whenever possible. In addition, further research into the biology of IBC may help to elucidate the mechanisms underlying its aggressive clinical behavior and to assist in the development of therapies targeted for this specific population.

AB - Opinion statement: Inflammatory breast cancer (IBC) is an uncommon and aggressive presentation of locally advanced breast cancer that is potentially curable when localized but may be associated with distant metastasis in up to one-third of patients at presentation. The diagnosis of IBC is made based on clinical features, including the presence of skin edema and erythema involving at least one-third of the breast, with or without a mass, and usually associated with dermal lymphatic invasion (DLI) on skin biopsy. Management requires combined modality therapy, including neoadjuvant chemotherapy with an anthracycline and taxane-based regimen, followed by surgery and radiotherapy, plus concurrent anti-HER2 therapy for HER2-positive disease, and endocrine therapy for at least 5 years after surgery for estrogen-receptor-positive disease (Fig. 1). There have been few large clinical trials focused on IBC; therefore, most data regarding treatment are derived from retrospective analyses, small studies, and extrapolation of results from trials of noninflammatory locally advanced breast cancer. Patients with IBC should be encouraged to enroll in clinical trials whenever possible. In addition, further research into the biology of IBC may help to elucidate the mechanisms underlying its aggressive clinical behavior and to assist in the development of therapies targeted for this specific population.

KW - Anthracycline

KW - Inflammatory breast cancer

KW - Taxane

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84873712991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873712991&partnerID=8YFLogxK

U2 - 10.1007/s11864-012-0214-4

DO - 10.1007/s11864-012-0214-4

M3 - Article

C2 - 23160756

AN - SCOPUS:84873712991

VL - 14

SP - 66

EP - 74

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 1

ER -